LBRX — LB Pharmaceuticals Inc Common Stock

Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: NASDAQ
• Employees: 16
• Website: https://lbpharma.us

Latest SEC filings for LBRX

• SCHEDULE 13G/A — 2026-10-13
• EFFECT — 2026-10-06
• S-3ASR — 2026-10-01
• POS AM — 2026-10-01
• S-3ASR — 2026-10-01
• 8-K — 2026-09-15
• 424B3 — 2026-09-15
• 424B3 — 2026-09-03
• 8-K — 2026-09-03
• 10-Q — 2026-08-11

Latest LBRX news

• 2026-10-09 — LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire Inc.)
• 2026-10-06 — LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment (globenewswire.com)
• 2026-09-28 — LB Pharmaceuticals Inc (NASDAQ:LBRX) Stock Has Average Target Price of $49.62

Abrir análisis completo

Educational tool only — not investment advice.